Alkermes Expects Gradual Ramp-Up For Lybalvi Launch
Alkermes’ combo pill of olanzapine and samidorphan gets US FDA approval; company predicts $10m first-year sales as schizophrenia/bipolar patients cycle through treatment options, including generics.
You may also be interested in...
After a year of strong commercial performance for Lybalvi and with IL-2 drug nemvaleukin in registration-enabling studies, Alkermes is ready to separate its neuroscience and oncology businesses.
PODCAST: Datamonitor Healthcare analysts explore the three key psychiatric disorder markets from current market leaders to promising pipeline candidates and novel mechanisms.
On the heels of clinical failures for Nektar’s pegylated IL-2 candidate bempeg, Alkermes’ CEO argued its high-dose IL-2 for cancer is well differentiated during earnings call. Schizophrenia drug Lybalvi posted solid first full-quarter revenue, prescription numbers.